Kornimate/medical-research-clean huggingface dataset:
improving parent-child interactions to enhance child health

Conditions: Child Obesity

Summary: childhood obesity is a formidable public health issue in the united states, disproportionately affecting children from lower socioeconomic status households. onset of obesity predicts cardiometabolic risks and other health problems in adolescence and into adulthood; thus, effective and early prevention is critical. healthy parenting may play a pivotal role in preventing early childhood obesity. warm, responsive, and consistent parenting is associated with the development of child self-regulation as well as healthy eating and physical activity practices, and thus may be protective against obesity risk. targeting the parent-child relationship may be especially important when facilitating behavior change in parents who have ongoing stressors (e.g., low-income families). the proposed study aims to test an adaptation of parent-child interaction therapy (pcit), an innovative parent management program that improves the parent-child relationship and enhances general parenting skills through the use of therapeutic in vivo coaching. our adapted version, pcit-health, is a selective-prevention intervention that includes content specific to improving parent-child interactions and parenting in obesity-salient contexts, such as mealtime and child screen time. this project will elucidate novel approaches to, and novel targets of, early childhood obesity prevention and will provide data critical to test pcit-health in a large-scale randomized controlled trial. parent-child dyads will be randomly assigned to pcit-health or a waitlist control in order to accomplish the following aims: aim 1: to assess the acceptability and feasibility of the pcit-health delivery and assessment methods in low-income parents of overweight young children ages 3 to 6 years. aim 2: to test the preliminary efficacy and estimate the effect size of pcit-health on changes in child bmi z-score (primary outcome) from baseline to (1) intervention completion and (2) 6-month post-intervention. aim 3: to explore the effect of pcit-health on the following secondary outcomes: (1) parent-child relationship quality, (2) parent behavior management skills, (3) child self-regulation, (4) child eating behaviors, (5) child physical activity, and (6) child screen media use.


Eligibility criteria:
inclusion criteria: * child bmi \> 5th percentile * child born at 37+ weeks gestation, with no significant neo- or perinatal complications. exclusion criteria: * child is experiencing clinical levels of behavior problems * history of food allergies or medical problems or medications affecting appetite or weight * non-fluency in english * significant child or parent developmental delay * child currently in state custody * family currently involved with child protective services * caregiver is receiving or has plans to receive other behavioral parenting interventions
effects of high-flow oxygen therapy and non-invasive ventilation on lung volumes and on upper airway

Conditions: Respiratory Failure

Summary: respiratory failure is the most frequent organ failure and cause for admission in the intensive care unit (icu) . it is a severe complication with an icu mortality ranged from 31% to 33%. symptomatic treatment of hypoxemic respiratory failure is a controversial topic with different options: 1) standard oxygen therapy, 2) high flow nasal cannula oxygen therapy (hfnc) and 3) non-invasive ventilation (niv). the aim of the study is to compare hfnc versus niv ventilation using ct scan. the hypothesis of this study is that in hypoxemic critically ill patients, the increase of lung volumes with niv would be significantly higher than the increase of lung volumes with hfnc.


Eligibility criteria:
inclusion criteria: * patient with hypoxemia at any time of icu stay defined as follow: standard oxygen therapy flow ≥ 3l/min to maintain a pulsed oxygen saturation ≥ 95% * adult (age ≥ 18 years) * (2) a ct scan prescribed by the physician in charge of the patient as part of the exploration of the patient's pathology and not as part of a "dedicated" prescription for the study. exclusion criteria: * niv contraindication (need for immediate endotracheal intubation and mechanical ventilation; hemodynamic instability defined by systolic blood pressure \< 90 mmhg or mean blood pressure \< 65 mmhg, use of vasopressors; glasgow coma scale score of 12 points or less) * history of recent facial trauma not compatible with the use of nasal cannulas * pregnancy * refusal of study participation * protected person * patient not affiliated to the social security system or not benefiting from such a system * lack of signed informed consent

Keywords: intensive care non-invasive ventilation high-flow nasal oxygen therapy hypoxemic respiratory failure upper airway
forward pro study interventional post-market study with the evolut™ pro system

Conditions: Aortic Valve Stenosis

Summary: prospective, single-arm, multi-center, interventional post-market study. after signing informed consent, eligible subjects will be implanted with the ce marked evolut™ pro system. the investigation purpose is to evaluate the acute and long term clinical performance and safety of evolut™ pro in a routine hospital setting in patients with symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement within the approved intended use in local geography.

approximately 600 subjects implanted with the evolut™ pro at up to 40 sites in europe. other regions may be added depending on the regulatory status of the device.

Eligibility criteria:
inclusion criteria: * symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement * high or greater risk for surgical aortic valve replacement as estimated by the heart team or, 75 years or older and at intermediate risk for surgical avr (sts risk score ≥4% or with an estimated hospital mortality ≥4% as assessed by the heart team) * acceptable candidate for treatment with the evolut™ pro system in conformity with the instructions for use and the local regulations * able and willing to return to the implanting site at the following follow-up visits: 1-year, 3-year and 5-year * written informed consent obtained without assistance from a legal representative prior to enrollment in the study. exclusion criteria: * known hypersensitivity or contraindication to aspirin, heparin (hit/hitts) and bivalirudin, ticlopidine, clopidogrel, nitinol (titanium or nickel), or sensitivity to contrast media, which cannot be adequately premedicated * preexisting mechanical heart valve in aortic position * ongoing sepsis, including active endocarditis * anatomically not suitable for the evolut™ pro system * estimated life expectancy of less than 1 year * participating in another trial that may influence the outcome of this study * need for emergency surgery for any reason * inability to understand and respond to the quality of life questionnaire
survey based discrete choice experiment study in prostate cancer (decider) study

Conditions: Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer

Summary: the purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (adt) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mhspc). this study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

the study will develop and administer a discrete-choice experiment (dce) to quantify tradeoff preferences of participants with mhspc and locally-advanced prostate cancer in various countries. data/surveys are being collected in: united states, canada, uk, france, spain, japan, china and south korea.

Eligibility criteria:
inclusion criteria: for interviews (attribute prioritization and pretest interviews) * diagnosis of mhspc with or without previous experience with adt * able to read and understand the survey language * able to provide informed consent for online survey * diagnosis of mhspc or locally-advanced prostate cancer with or without previous experience with adt * able to read and understand the survey language * able to provide informed consent exclusion criteria: not applicable

Keywords: prostate cancer metastatic hormone-sensitive prostate cancer observational
whole person care research program of the suicide cases consultative services

Conditions: Suicide

Summary: this project aims to provide more treatment options to suicide patients to further enhance the holistic medical services in far eastern memorial hospital. it focuses on high-risk cases, especially those whose suicidal behaviors are triggered by interpersonal/or emotional problems because psychological counseling or interpersonal growth groups of services have been shown to be beneficial to this population.


Eligibility criteria:
inclusion criteria: * above 20 years old, survivors from suicide. exclusion criteria: * under 20 years old * prisoner * suffer from a serious illness * foreigner/ can't speak chinese * the people who can't express themselves * can not be interviewed in femh * people with severe physical or psychological symptoms

Keywords: individual counseling service group counseling service
validation and optimisation of ultrasound diagnosis of adenomyosis

Conditions: Adenomyosis

Summary: defining ultrasound criteria for normal uterine biometry and assessing the prevalence of repeat abortions in patients with abnormalities of the uterine cavity

adenomyosis is a gynaecological disorder with a high prevalence in women of childbearing age and is characterised by the presence of glands and endometrial stroma within the myometrium, associated or not with hypertrophy and hyperplasia of the surrounding myometrium. adenomyosis may cause pelvic pain and/or abnormal uterine bleeding. transvaginal ultrasound may be considered the main non-invasive diagnostic modality for the diagnosis of adenomyosis. the aim is to optimise the ultrasound diagnosis of uterine pathology and in particular of adenomyosis by defining uterine biometric parameters (longitudinal, transverse and anteroposterior diameters and their ratios; uterine volume) allowing patients to be divided into 3 groups: * uterus affected by adenomyosis (group a): adenomyosis is a gynaecological condition with high prevalence in women of childbearing age and is characterised by the presence of endometrial tissue (innermost layer of the uterus) within the uterine muscle. adenomyosis can cause abdominal pain and abnormal uterine bleeding. * uterus affected by fibromatosis (group b): uterine fibromatosis is a gynaecological condition characterised by the appearance of numerous fibroids in the uterus. it is a very frequent condition in the general population and its frequency increases as the age of the patients increases. * normal uterus (group c). transvaginal ultrasound, although a reference diagnostic tool, still remains an operator-dependent examination to date: our secondary objective is to build models that can simplify diagnosis through the use of artificial intelligence. the aim is to create various artificial intelligence software that can 'learn to make a diagnosis'. this method has already been applied in radiology, proving capable of discriminating between benign and malignant tumours from images from different diagnostic methods with performance similar to that of experienced radiologists.

Eligibility criteria:
inclusion criteria: * age between 18 and 60; * obtaining informed consent exclusion criteria: * hysterectomised patients; * virgo patients (hymenal integrity); * patients reporting intolerance to transvaginal ultrasound; * gynaecological oncology; * recent pregnancy or childbirth (within 6 months); * menopausal patients

Keywords: adenomyosis gynaecology ultrasound
effectiveness of aspirin in compare with heparin plus aspirin in recurrent pregnancy loss treatment

Conditions: Recurrent Pregnancy Loss

Summary: this study evaluated the effect of anticoagulant treatment on the live-birth rate in women with a history of at least two continuous unexplained miscarriages or thrombophilia. it also compared two methods of treatment with aspirin and aspirin plus heparin.


Eligibility criteria:
inclusion criteria: * unexplained recurrent miscarriage, * women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for fv leiden g1691a, prothrombin gene g20210a (fii g20210a), and methyltetrahydrofolate reductase c677t (mthfr c677t) exclusion criteria: * abnormal karyotypes of both partners, * uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy, * abnormal ovaries and abnormal endocrine tests.
photographic rhinometry following derm/mohs surgery for skin cancers

Conditions: Skin Cancer

Summary: dermatological surgeons and patients routinely notice alterations in nasal shape and size following surgery and reconstruction. there is no uniform approach to objectively measure these changes. anthropometric measurements are routinely used in rhinoplasty to assess outcomes, but they are time consuming and have not been reported as being used by dermatological surgeons. soft-tissue measurements in profile photographs have been demonstrated to be useful for objective measurement of nasal change following surgery. this is a follow up study of the pilot study to assess the feasibility of photographic rhinometry as an objective tool, and (ii) to quantify changes following common dermatological surgical procedures on the nose. this follow-up study will aim to recruit a larger population sample to better quantify some of the changes occurring post-operatively.


Eligibility criteria:
inclusion criteria: * gender: male and female participants * type of cancer: undergoing surgery for removal of basal cell carcinoma (bcc), squamous cell carcinoma (scc)) exclusion criteria: * cases unable to consent to participation in the study * patients who are unable to complete the study assessments * patients below 18 years of age * patients undergoing surgery for other types of skin cancer
stress prevention at work: intervention efficacy and implementation process evaluation

Conditions: Stress, Psychological

Summary: the stress prevention at work (spa) project intends to evaluate the method named productivity measurement and enhancement system (promes) as a stress preventive approach among health care employees.

stress-related illnesses are today together with musculoskeletal disorders the predominant cause of production loss and absenteeism. the risks of developing stress-related mental illness is today well established, however, it is less studied how this can be successfully treated or prevented in workplaces through interventions. the spa project intends to evaluate the method the productivity measurement and enhancement system (promes). the method is mainly evaluated for production improvement, but there are indications that it also has stress-reducing effect on working groups. the method gives employees within health care opportunities to participate actively in productivity-enhancing measures. the employees, along with their immediate supervisors, identify and prioritize responsive and desirable results in all of the activities important dimensions. international studies have shown that participation (participation) has positive effects on employee performance and attitudes. the aim of this study is to test whether efforts in targeting the organization and work environment can reduce stress and prevent stress-related ill health in the workplace. primary outcomes of the study are tense work i.e. imbalance between demand and control and other primary indicators of stress, such as sleep and recovery. the hypothesis in study 1 is that productivity enhancing workplace interventions based on a participative approach also increases employees' sense of control and control over their own work. this in turn means that the method also could be used to reduce the occurrence of tense work and thus affect / reduce the stress-related illness.

Eligibility criteria:
inclusion criteria: * all employees (18-67 years) employed at the intervention and control primary care units, who were actually working at the time for this study exclusion criteria: * employees absent due to long-term illness, * employees absent due to parental leave * employees absent due to long-term studies

Keywords: work related stress
a 16 week study evaluating levetiracetam in the treatment of post herpetic neuralgia (phn)

Conditions: Neuralgia, Postherpetic

Summary: 16 week trial assessing the efficacy, safety, and tolerability of levetiracetam compared with placebo in the treatment of postherpetic neuralgia.


Eligibility criteria:
inclusion criteria: * male or female outpatient greater than or equal to 18 years of age. * suffering presently from neuralgia, which has been present for at least 3 months since healing of acute herpes zoster skin rash. * phn pain at entry into the study must meet the following criteria: a vas of at least 40 mm at visit 2 (to assess pain intensity during the past week) and with an average daily score of at least 4 on the pis during the baseline period as evaluated on a minimum of 4 days. * an estimated creatinine clearance of at least 50 ml/min. exclusion criteria: * receiving professional psychological support (such as cognitive behavioral therapy) currently or within 2 weeks prior to visit 1 specifically for coping with phn. * previous neurolytic or neurosurgical therapy for phn, at any time in the subject's history or treatment with tens (transelectroneuro stimulation) currently or within the past 2 weeks. * known co-existent source of pain or painful peripheral neuropathy. * known significant neurological disorder other than the study disease or a condition which can mimic stroke with distal neurological deficit (amyotrophy, radiculopathy, history of tias, multiple sclerosis, or any amputations). * conditions known to be associated with immunosuppressive states. * clinically significant major depression defined as a beck depression inventory score \> 21 at selection including those with a history of bipolar disorder.

Keywords: postherpetic neuralgia (phn) levetiracetam keppra nerve pain
flu-bu-mel conditioning regimen for myeloid disease

Conditions: Relapse Rate After Allo-HSCT

Summary: for patients with acute myeloid leukemia (aml) or myelodyspasia syndrome undergoing allo-hsct, the conditioning regimen will be 5-day fludarabine, 2-day busulifan and 2-day melphalan

for patients with acute myeloid leukemia (aml) or myelodyspasia syndrome undergoing allo-hsct, the conditioning regimen will be fludarabine (30mg/m2, d-7 to d-3) + busulifan 3.2mg/kg (d-7 to d-6) + melphalan 70mg/m2 (d-4 and d-3). the gvhd prophylaxis will be pt-cy (cyclophosphamide 50mg/kg d+3 and d+4) + low-dose atg (2.5mg/kg) on d+15.

Eligibility criteria:
inclusion criteria: * acute myeloid leukemia (cr1 or cr2) or myelodysplasia syndrome * patients with hla matched sibling, unrelated or haplo-identical donor exclusion criteria: * patients with active infection * patients with abnormal liver function damage: alt/ast above 2x normal range * patients with abnormal renal function damage scr\>160µmol/l; * patients with insufficient pulmonary function (fev1，fvc，dlco\<50%）and heart failure or with ef \<50%) * patients with mental instability or unwilling to give inform consent
the genital microbiome of male partners of women with recurrent bv undergoing vaginal microbiome transplantation

Conditions: Bacterial Vaginosis; Microbial Colonization

Summary: there is strong observational evidence that sexual activity plays a key role in bacterial vaginosis (bv) acquisition and recurrence. microbiological data support the contribution of sexual transmission to the pathogenesis of bv through the exchange of bv-associated bacteria (bvab) between sexual partners. although bv epidemiology strongly suggests sexual transmission, treatment of sexual partners is not recommended, based on prior treatment studies of male partners of women with recurrent bv, which showed no benefit with male treatment. nevertheless, male condom use is highly protective against recurrent bv. this study aims to evaluate the male-partner's genital microbiome as a potential source of bv-recurrence in women undergoing vaginal microbiota transplantation (nct04517487), and whether disinfection can eliminate bv-associated penile microbiome.


Eligibility criteria:
inclusion criteria: * the subject has s female partner who participates in vmt study ( nct04517487). * the subject is defined by the woman as her male regular partner. * willing to use a condom as instructed by the protocol. * willing to comply with decolonization protocol. exclusion criteria: * a known skin disease involving the penile skin. * a known sensitivity to chlorhexidine gluconate * any of the partners (female/male) has more than one sexual partner.

Keywords: penile microbiome vaginal microbiome transplant male partners bacterial vaginosis
botulinum toxin in peripheral neuropathic pain

Conditions: Postherpetic Neuralgia; Diabetic Polyneuropathies; Other Polyneuropathies

Summary: pain due to peripheral nerve lesion remains extremely difficult to treat and current treatments have onl moderate efficacy and/or side effects. the investigators have previously demonstrated the long term efficacy of botulinum toxin type a (btx-a) in a small group of patients with post-traumatic/postherpetic neuralgia and allodynia. the present study aims to a/ confirm the efficacy of repeated applications of btx-a in a larger group of patients with peripheral neuropathic pain with or without allodynia(primary outcome) ; b/ evaluate its mechanisms of action ; c/analyse the predictors of response ;d/analyse whether the second injection is associated with a therapeutic gain. this will be a randomized placebo controlled study. a total of 30 patients will be randomized to receive either btx-a (subcutaneous injection in the painful area) or placebo. each injection will be repeated within at least 3 months depending on the duration of efficacy. skin punch biopsies will be performed before and 1 month after btx-a administration. the investigators postulate that this study will confirm the clinical efficacy and good safety of repeated administrations of btx-a in the treatment of peripheral neuropathic pain.


Eligibility criteria:
inclusion criteria: men or women aged 18 to 85 years spontaneous pain with a minimal intensity of 4/10 on numerical scle pain present for at least 6 months pain related to painful mononeuropathy or sensory polyneuropathy able to understand the protocol and comply to the requirements of the study written informed consent painful area limited to a maximum of 240 cm2 exclusion criteria: facial pain litigation (pending) unstable condition responsible for neuropathic pain (ie, unstable immunological disease...) hiv or chemotherapy induced neuropathy contraindications to btx-a (neuromuscular disease, hypersensitivity, infection, coagulation disorder, pregnancy) other pain more severe than neuropathic pain no compliance with the self diary drug abuse or alcoholism severe major depression cognitive impairment other research protocol within the last 30 days

Keywords: botulinum toxin neuropathic pain randomized controlled trial